BHSTConsumer Defensive · Packaged FoodsThe 3 Wall Street analysts covering BioHarvest Sciences, Inc. hold a median 12-month price target of $11 — +648.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 3 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores BioHarvest Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (85): Smaller than most of the companies we track.
Momentum (3): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BHST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +648.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | Maxim Group | Maintains | Buy | $12 → $5.00 |
| 12 Aug 2026 | Roth Capital | Maintains | Buy | $10 → $8.00 |
| 19 Feb 2026 | Roth Capital | Initiates | Buy | — |
| 19 Feb 2026 | Roth Capital | Initiates | Buy | $10 |
| 8 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Dec 2024 | Maxim Group | Initiates | Buy | — |
| 11 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Dec 2024 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BHST appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 2 Oct 2026, BioHarvest Sciences, Inc. returned −84.0% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 70% of US stocks
Cheaper than 50% of US stocks
Cheaper than 80% of US stocks
Higher than 36% of US stocks
Higher than 40% of US stocks
Higher than 71% of US stocks
Higher than 20% of US stocks
Higher than 13% of US stocks
Higher than 10% of US stocks
Higher than 25% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BioHarvest Sciences, Inc. has a market value of $33.3M and an enterprise value of $33.2M.
Revenue in the twelve months to 30 June 2026: $35.5M. The latest quarter grew 3.8% year on year.
Net income over the same four quarters: −$11.1M, a −31.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$10.8M.
Trailing P/E: −2.4×; forward P/E: −4.4× — the forward figure prices analyst consensus estimates, not reported earnings.
BioHarvest Sciences, Inc. employs 89 people — $399K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BioHarvest Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
BioHarvest Sciences' board has authorized a share repurchase program covering up to 5% of its outstanding common shares. The program will be structured as a normal course issuer bid, in line with Canadian practice.
Why it matters — A buyback of this size signals management's confidence in the company and could reduce the number of shares outstanding.
BioHarvest Sciences announced that its Board of Directors has authorized a share repurchase program, structured as a normal course issuer bid in accordance with Canadian practices. The Board believes the market price of the Company's common shares may not fully reflect the underlying value of its business and future growth prospects.
Why it matters — A share buyback signals that management views the company's shares as undervalued, which could be of interest to investors tracking BioHarvest Sciences.
BioHarvest Sciences announced the launch of single-dose VINIA Daily Chews, a new delivery format for its first consumer product designed to broaden the addressable market and expand usage occasions. The company says the format demonstrates the versatility of its Botanical Synthesis platform and its ability to help CDMO partners move from plant-cell compositions to differentiated consumer products.
Why it matters — A BHST watcher would care because the new format expands the commercial reach of its flagship VINIA product and showcases progress toward industrial-scale Botanical Synthesis, which underpins its business model.
BioHarvest Sciences announced that its CEO, Zaki Rakib, will present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York City.
Why it matters — BHST watchers would care because the company's CEO will gain exposure to investors at a major global investment conference, which could raise awareness of the company's Botanical Synthesis technology.
BioHarvest Sciences Inc plans a dual listing of its ordinary shares on the Tel Aviv Stock Exchange, with trading expected to begin on September 8, 2026. The company, already listed on the Nasdaq Capital Market, expects the TASE listing to give Israeli investors access to its shares.
Why it matters — A TASE dual listing would broaden BioHarvest's investor base by giving Israeli investors direct access to its shares, potentially increasing liquidity and visibility for the company.
The 3 Wall Street analysts covering BioHarvest Sciences, Inc. have a median 12-month price target of $11, with estimates ranging from $5 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering BioHarvest Sciences, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioHarvest Sciences, Inc. 41 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Oct 2026, BioHarvest Sciences, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +648.3% from the last close, and Ticker Nerd's factor model ranks BioHarvest Sciences, Inc. 41 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BioHarvest Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BHST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $15 over the next 12 months.
BioHarvest Sciences, Inc. returned -84.0% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
BioHarvest Sciences Inc. is a biotechnology company focused on Botanical Synthesis, a proprietary platform used to produce plant-based compounds without growing the underlying plant.
The most recent item we track (Proactive Investors, 29 Sept 2026): "BioHarvest Sciences launches buyback of up to 5% of shares". BioHarvest Sciences' board has authorized a share repurchase program covering up to 5% of its outstanding common shares. The program will be structured as a normal course issuer bid, in line with Canadian practice.
BioHarvest Sciences Inc. is a biotechnology company focused on Botanical Synthesis, a proprietary platform used to produce plant-based compounds without growing the underlying plant. Its core business centers on developing and commercializing science-based nutraceutical, health, wellness, pharmaceutical, and cosmeceutical solutions, alongside contract development and manufacturing services for third-party partners. The company’s product portfolio includes consumer wellness offerings such as VINIA, a red grape cell supplement, and it also works on plant-derived ingredients for foods, beverages, and specialty applications. BioHarvest Sciences Inc. serves markets spanning dietary supplements, functional foods, health ingredients, and advanced botanical molecules, positioning itself at the intersection of biotechnology and plant-based product innovation. Headquartered in Vancouver, Canada, the company operates with activities in Israel and the United States.
CEO Dr. Zaki Rakib Ph.D. · 89 employees · Canada · https://www.bioharvest.com
